Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin ReckDelvys Rodríguez-AbreuAndrew G RobinsonRina HuiTibor CsősziAndrea FülöpMaya GottfriedNir PeledAli TafreshiSinead CuffeMary O'BrienSuman RaoKatsuyuki HottaTiciana A LealJonathan W RiessErin JensenBin ZhaoM Catherine PietanzaJulie R BrahmerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Pembrolizumab provides a durable, clinically meaningful long-term OS benefit versus chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.